Key result
Ranolazine markedly increases coronary flow reserve in patients with nonobstructive coronary artery disease.
Why the study?
Microvascular dysfunction in patients with nonobstructive coronary artery disease is increasingly recognized as an important health issue, prompting evaluation of the effectiveness of ranolazine in improving coronary microvascular function.
Does ranolazine improve coronary microvascular function in patients with nonobstructive coronary artery disease?
Systematic Review (n=379)
Does ranolazine improve coronary microvascular function in patients with nonobstructive coronary artery disease?
Standardized Mean Difference: 1.16 (95% CI 0.4–1.89)
p-value: p=0.002
Ranolazine improves coronary flow reserve, myocardial perfusion, and angina symptoms in patients with nonobstructive coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Ranolazine may be considered for microvascular dysfunction in nonobstructive CAD; extends limited prior trial data.
Ling et al. (2024) conducted a systematic review in nonobstructive coronary artery disease (n=379). Ranolazine vs. control was evaluated on coronary flow reserve (CFR) (SMD 1.16, 95% CI 0.4-1.89, p=0.002). Ranolazine significantly increased coronary flow reserve (SMD 1.16; 95% CI 0.4-1.89; P=0.002) over an 8 to 12-week follow-up in patients with nonobstructive coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: